SCHEDULE Filed 2025-03-10 Event 2025-03-06 SEC 0001415889-25-007529 →

RA CAPITAL MANAGEMENT, L.P. → Janux Therapeutics, Inc. JANX

Stake: 19.90% Shares: 11,971,377 CUSIP: 47103J105 Class: Common Stock, par value $0.001 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 29/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Filer track record (20 filings): 0% 90d win rate, +0.0% 90d edge
High conviction ownership stake (19.9%)
Held by 1 tracked 13F institutional manager
9 NPORT-P mutual funds holding CUSIP
Elevated short days-to-cover (6.2 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

0 buys · 0 sales · 1 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

88 filings by this filer

87 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 6.20

5,327,163 shares short · -6.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $13.27M

Point72 Asset Mgmt

Post-Filing Returns · since 2025-03-06 on JANX

+1 day

0.0%

+5 days

0.0%

+30 days

0.0%

+60 days

0.0%

+90 days

0.0%

+180 days

0.0%

Anchor price 16.15 on closest trading day on/after 2025-03-06. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-07-08	Campbell David Alan	director, officer	Option exercise	7,000	$4.21	$29K

Other 13D/G Filings on Janux Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2024-10-25	SC	Avalon Ventures XI, L.P.	—	—	view →

Other Filings by RA CAPITAL MANAGEMENT, L.P.

Filed	Form	Issuer	Stake	Shares
2026-10-26	SCHEDULE 13G	Alector, Inc.	—	—	view →
2026-10-22	SCHEDULE 13G	Frazier Life Sciences Acquisition Corp. II	—	—	view →
2026-09-22	SCHEDULE 13G	BetterLife Pharma Inc.	—	—	view →
2026-09-21	SCHEDULE 13D/A	SIONNA THERAPEUTICS, INC.	14.30%	6,476,193	view →
2026-09-17	SCHEDULE 13D/A	TYRA BIOSCIENCES, INC.	—	14,130,492	view →
2026-09-03	SCHEDULE 13G	JATT III Acquisition Corp	—	—	view →
2026-08-17	SCHEDULE 13G	Latigo Biotherapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13D/A	SEPTERNA, INC.	—	5,525,324	view →
2026-08-11	SCHEDULE 13D/A	Wave Life Sciences, Inc.	—	34,314,406	view →
2026-08-10	SCHEDULE 13D/A	SAB Biotherapeutics, Inc.	—	9,609,852	view →
2026-07-23	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC.	—	18,415,956	view →
2026-07-22	SCHEDULE 13D/A	Freenome, Inc.	—	15,367,270	view →
2026-07-21	SCHEDULE 13D/A	VOR BIOPHARMA INC.	—	12,937,855	view →
2026-07-20	SCHEDULE 13G	Agenus Inc.	—	—	view →
2026-07-07	SCHEDULE 13D/A	Climb Bio, Inc. CLYM	33.00%	23,249,186	view →
2026-07-02	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	4.10%	1,985,541	view →
2026-06-26	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	6.00%	2,915,742	view →
2026-06-24	SCHEDULE 13D/A	SOLID BIOSCIENCES INC. SLDB	—	12,036,126	view →
2026-06-22	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	3,654,307	view →
2026-06-18	SCHEDULE 13D	Parabilis Medicines, Inc. PBLS	23.80%	28,933,371	view →

Showing 20 of 87

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →